iRadimed Corporation (NASDAQ:IRMD) Stock Has Average Price Target of $120.00

iRadimed Corporation (NASDAQ:IRMD) has earned a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation, two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $120.00.

IRMD has been the subject of a number of research analyst reports. Needham & Company LLC began coverage on shares of iRadimed in a research note on Tuesday, September 22nd. They issued a “hold” rating for the company. Wall Street Zen lowered shares of iRadimed from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Weiss Ratings lowered shares of iRadimed from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday.

Insider Buying and Selling at iRadimed

In related news, Director Monty K. Allen sold 1,419 shares of the company’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $86.41, for a total transaction of $122,615.79. Following the sale, the director directly owned 19,581 shares of the company’s stock, valued at approximately $1,691,994.21. This represents a 6.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 34.60% of the company’s stock.

Hedge Funds Weigh In On iRadimed

Several large investors have recently added to or reduced their stakes in IRMD. BlackRock Inc. bought a new position in iRadimed in the 2nd quarter worth approximately $92,485,000. Ranger Investment Management L.P. acquired a new position in iRadimed during the 2nd quarter worth $9,398,000. Bank of New York Mellon Corp acquired a new position in iRadimed during the 2nd quarter worth $7,252,000. Rice Hall James & Associates LLC bought a new position in shares of iRadimed in the second quarter worth $2,909,000. Finally, Punch & Associates Investment Management Inc. acquired a new position in shares of iRadimed during the second quarter valued at $1,911,000. 92.34% of the stock is currently owned by institutional investors.

iRadimed Stock Up 1.3%

IRMD opened at $86.47 on Tuesday. iRadimed has a 52-week low of $70.80 and a 52-week high of $107.90. The company has a 50 day moving average of $87.00 and a two-hundred day moving average of $91.09. The company has a market cap of $1.11 billion, a P/E ratio of 48.31 and a beta of 0.91.

iRadimed (NASDAQ:IRMD) last announced its earnings results on Friday, July 31st. The medical equipment provider reported $0.46 EPS for the quarter, beating the consensus estimate of $0.44 by $0.02. The business had revenue of $20.47 million for the quarter, compared to the consensus estimate of $20.35 million. iRadimed had a return on equity of 23.45% and a net margin of 26.70%.iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. Research analysts anticipate that iRadimed will post 1.98 earnings per share for the current year.

iRadimed Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, August 28th. Shareholders of record on Friday, August 14th were issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend was Friday, August 14th. iRadimed’s dividend payout ratio (DPR) is currently 44.69%.

iRadimed Company Profile

IRadimed Corporation develops, manufactures and markets medical devices designed for use in magnetic resonance imaging (MRI) environments. The company focuses on addressing the challenges of providing continuous infusion therapy and patient monitoring while patients are undergoing MRI procedures.

Its products include the MRidium MRI-compatible infusion pump system, which is designed to deliver intravenous medications and fluids without interfering with MRI operations, and MRI-compatible patient-monitoring systems used to track vital signs during imaging.